Cargando…
Erratum. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241–1249
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Diabetes Association
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5439412/ https://www.ncbi.nlm.nih.gov/pubmed/28420698 http://dx.doi.org/10.2337/dc17-er06 |
| _version_ | 1783237945277284352 |
|---|---|
| author | Kazda, Christof M. Ding, Ying Kelly, Ronan P. Garhyan, Parag Shi, Chunxue Lim, Chay Ngee Fu, Haoda Watson, David E. Lewin, Andrew J. Landschulz, William H. Deeg, Mark A. Moller, David E. Hardy, Thomas A. |
| author_facet | Kazda, Christof M. Ding, Ying Kelly, Ronan P. Garhyan, Parag Shi, Chunxue Lim, Chay Ngee Fu, Haoda Watson, David E. Lewin, Andrew J. Landschulz, William H. Deeg, Mark A. Moller, David E. Hardy, Thomas A. |
| author_sort | Kazda, Christof M. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-5439412 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2017 |
| publisher | American Diabetes Association |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-54394122018-06-01 Erratum. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241–1249 Kazda, Christof M. Ding, Ying Kelly, Ronan P. Garhyan, Parag Shi, Chunxue Lim, Chay Ngee Fu, Haoda Watson, David E. Lewin, Andrew J. Landschulz, William H. Deeg, Mark A. Moller, David E. Hardy, Thomas A. Diabetes Care Errata American Diabetes Association 2017-06 2017-04-18 /pmc/articles/PMC5439412/ /pubmed/28420698 http://dx.doi.org/10.2337/dc17-er06 Text en © 2017 by the American Diabetes Association. http://www.diabetesjournals.org/content/licenseReaders may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license. |
| spellingShingle | Errata Kazda, Christof M. Ding, Ying Kelly, Ronan P. Garhyan, Parag Shi, Chunxue Lim, Chay Ngee Fu, Haoda Watson, David E. Lewin, Andrew J. Landschulz, William H. Deeg, Mark A. Moller, David E. Hardy, Thomas A. Erratum. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241–1249 |
| title | Erratum. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241–1249 |
| title_full | Erratum. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241–1249 |
| title_fullStr | Erratum. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241–1249 |
| title_full_unstemmed | Erratum. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241–1249 |
| title_short | Erratum. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241–1249 |
| title_sort | erratum. evaluation of efficacy and safety of the glucagon receptor antagonist ly2409021 in patients with type 2 diabetes: 12- and 24-week phase 2 studies. diabetes care 2016;39:1241–1249 |
| topic | Errata |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5439412/ https://www.ncbi.nlm.nih.gov/pubmed/28420698 http://dx.doi.org/10.2337/dc17-er06 |
| work_keys_str_mv | AT kazdachristofm erratumevaluationofefficacyandsafetyoftheglucagonreceptorantagonistly2409021inpatientswithtype2diabetes12and24weekphase2studiesdiabetescare20163912411249 AT dingying erratumevaluationofefficacyandsafetyoftheglucagonreceptorantagonistly2409021inpatientswithtype2diabetes12and24weekphase2studiesdiabetescare20163912411249 AT kellyronanp erratumevaluationofefficacyandsafetyoftheglucagonreceptorantagonistly2409021inpatientswithtype2diabetes12and24weekphase2studiesdiabetescare20163912411249 AT garhyanparag erratumevaluationofefficacyandsafetyoftheglucagonreceptorantagonistly2409021inpatientswithtype2diabetes12and24weekphase2studiesdiabetescare20163912411249 AT shichunxue erratumevaluationofefficacyandsafetyoftheglucagonreceptorantagonistly2409021inpatientswithtype2diabetes12and24weekphase2studiesdiabetescare20163912411249 AT limchayngee erratumevaluationofefficacyandsafetyoftheglucagonreceptorantagonistly2409021inpatientswithtype2diabetes12and24weekphase2studiesdiabetescare20163912411249 AT fuhaoda erratumevaluationofefficacyandsafetyoftheglucagonreceptorantagonistly2409021inpatientswithtype2diabetes12and24weekphase2studiesdiabetescare20163912411249 AT watsondavide erratumevaluationofefficacyandsafetyoftheglucagonreceptorantagonistly2409021inpatientswithtype2diabetes12and24weekphase2studiesdiabetescare20163912411249 AT lewinandrewj erratumevaluationofefficacyandsafetyoftheglucagonreceptorantagonistly2409021inpatientswithtype2diabetes12and24weekphase2studiesdiabetescare20163912411249 AT landschulzwilliamh erratumevaluationofefficacyandsafetyoftheglucagonreceptorantagonistly2409021inpatientswithtype2diabetes12and24weekphase2studiesdiabetescare20163912411249 AT deegmarka erratumevaluationofefficacyandsafetyoftheglucagonreceptorantagonistly2409021inpatientswithtype2diabetes12and24weekphase2studiesdiabetescare20163912411249 AT mollerdavide erratumevaluationofefficacyandsafetyoftheglucagonreceptorantagonistly2409021inpatientswithtype2diabetes12and24weekphase2studiesdiabetescare20163912411249 AT hardythomasa erratumevaluationofefficacyandsafetyoftheglucagonreceptorantagonistly2409021inpatientswithtype2diabetes12and24weekphase2studiesdiabetescare20163912411249 |